2026 年 02 月 06 日 | C0062@capital.com.tw | | | --- | --- | | 王睿哲 目标价(港元) | 26.5 | 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | H 股价(2026/2/5) | | 20.52 | | 恒生指数(2026/2/5) | | 26,885.24 | | 股价 12 个月高/低 | | 28.80/12.61 | | 总发行股数(百万) | | 2,670.43 | | H 股数(百万) | | 540.97 | | H 市值(亿港元) | | 111.01 | | | | 上海复星高科技 | | 主要股东 | | (集团)有限公司 | | | | (36.15%) | | 每股净值(元) | | 18.06 | | 股价/帐面净值 | | 1.14 | | | 一个月 | 三个月 一年 | | 股价涨跌(%) | -0.97% | -9.92% 62.68% | 近期评等 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 2025/12/10 | 21 ...

Investment Rating - The report assigns an "Accumulate" rating to the company [1][11][6]. Core Insights - The company is a leader in domestic surgical robotics, driving advancements in surgical procedures through continuous technological innovation. With rapid growth in global clinical surgical volumes, the company is experiencing significant revenue growth alongside increasing domestic sales and commercialization in overseas markets [2][11]. Summary by Sections 1. Domestic Surgical Robotics Leader - The company was founded in May 2017 in Shenzhen and is the first in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots. It has developed a "three-in-one" surgical solution combining multi-port, single-port, and remote systems [15][11]. - The company has achieved the highest sales volume among domestic manufacturers in 2024, with 20 units of its multi-port surgical robot sold in China, covering over 220 hospitals across 30 provinces [11][29]. - Revenue is projected to grow from RMB 0.48 billion in 2023 to RMB 1.6 billion in 2024, driven by increased sales and market acceptance of its products [29][30]. 2. Clinical Advantages of Surgical Robots - Surgical robots provide significant clinical benefits, including high precision, stability, and repeatability, which traditional laparoscopic surgeries struggle to achieve. This technology is transforming the landscape of minimally invasive surgeries [38][39]. 3. International Expansion and Sales Growth - The company has successfully entered overseas markets, securing five orders in 2024 and establishing a distribution network across five continents. By the end of 2025, it had signed global sales agreements for 118 units, with 72 units designated for international markets [11][29]. - The company’s internationalization efforts have marked a transition from initial market testing to large-scale expansion [11][29]. 4. Financial Projections - Revenue forecasts for 2025, 2026, and 2027 are RMB 4.32 billion, RMB 8.11 billion, and RMB 12.36 billion, respectively, reflecting substantial growth rates of 170% and 88% in the following years [4][11]. - The company is expected to turn profitable by 2026, with net profit projected to reach RMB 167 million by 2027, following a loss of RMB 219 million in 2024 [4][11]. 5. Management Team and R&D Strength - The management team, led by experienced founders, has built a proprietary technology platform supported by a multidisciplinary R&D team of 265 members. The company holds the highest number of patents in the Chinese surgical robotics sector [20][25]. - The company has established a comprehensive technology platform based on seven proprietary core technology modules, enhancing its competitive edge in the market [26][27].

Investment Rating - The investment rating for the company is "Buy" [4][9]. Core Insights - The company has launched the visionJet G3, which features significant upgrades in consumer orientation, including a fully upgraded avionics system, enhanced cabin comfort, and improved performance metrics such as maximum flight speed and payload capacity [1][4]. - The target customer base is high-net-worth individuals rather than professional pilots, focusing on smart and safe performance upgrades to address pain points during flights, which is expected to enhance customer acquisition and market penetration [1]. - The company is expanding its production capacity and improving its delivery structure, which is anticipated to lead to better order fulfillment and increased revenue from new product lines [1][4]. Financial Projections - Revenue is projected to grow from $1,068 million in 2023 to $1,902 million in 2027, with a compound annual growth rate (CAGR) of approximately 17.1% [3][8]. - Net profit is expected to increase from $91 million in 2023 to $237 million in 2027, reflecting a CAGR of about 22.8% [3][8]. - Earnings per share (EPS) is forecasted to rise from $0.59 in 2023 to $0.65 in 2027, with a decreasing price-to-earnings (P/E) ratio from 32.4 in 2023 to 12.4 in 2027, indicating potential valuation recovery [3][8].

证券研究报告·海外公司点评·旅游及消闲设施(HS) 百胜中国（09987.HK） 百胜中国 2025Q4 及全年业绩公告点评：质 地稳健的高股息龙头，维持推荐 买入（维持） | [Table_EPS] 盈利预测与估值 | 2024A | 2025A | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万美元） | 11,303 | 11,797 | 12,686 | 13,426 | 14,262 | | 同比(%) | 2.96 | 4.37 | 7.54 | 5.83 | 6.23 | | 归母净利润（百万美元） | 911.00 | 929.00 | 1,042.71 | 1,143.75 | 1,262.86 | | 同比(%) | 10.16 | 1.98 | 12.24 | 9.69 | 10.41 | | EPS-最新摊薄（美元/股） | 2.57 | 2.62 | 2.94 | 3.23 | 3.56 | | P/E（现价&最新摊薄） | 22.10 | 21.67 | 19.31 | 17.61 | ...

2026 年 02 月 06 日 | C0062@capital.com.tw | | | --- | --- | | 王睿哲 目标价(港元) | 26.5 | 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | H 股价(2026/2/5) | | 20.52 | | 恒生指数(2026/2/5) | | 26,885.24 | | 股价 12 个月高/低 | | 28.80/12.61 | | 总发行股数(百万) | | 2,670.43 | | H 股数(百万) | | 540.97 | | H 市值(亿港元) | | 111.01 | | | | 上海复星高科技 | | 主要股东 | | (集团)有限公司 | | | | (36.15%) | | 每股净值(元) | | 18.06 | | 股价/帐面净值 | | 1.14 | | | 一个月 | 三个月 一年 | | 股价涨跌(%) | -0.97% | -9.92% 62.68% | 近期评等 C o m p a n y U p d a t e C h i n a R e s e a r c h D e p ...

本文是由投资/产品专员而非分析师撰写的文章汇编。 它不构成研究报告，也不应被解释为研究报告，也不旨在提供 专业、投资或任何其他类型的建议或推荐。 CSIWM 个股点评 2026 年 2 月 6 日 京东健康 6618 HK 本文内容由 Kylie Kwok (郭凯欣) 提供 中信证券财富管理(香港) 产品及投资方案部 中国互联网行业 电话：(852) 2237 9250 / 电邮：wminvestmentsolutions@citics.com.hk 强劲的销售增长 摘要 中信证券财富管理与中信里昂研究观点一致。根据中信里昂研究 2026 年 2 月 3 日发布的题为《Robust sales growth》的报告，分析预计京东健康（JDH）将在 2025 年下半年保持强劲增长势头，收入将同比增长，主要是因 为"双 11"表现强劲，以及 12 月流感病例激增所导致。药品与保健品销售表现尤为突出，经调整息税前利润预计翻 倍，主要得益于毛利率扩张和运营杠杆效应，抵消了线下门店投资。分析指出，预计京东健康在 2026 年收入实现同 比增长但且上行风险显著，因为原研药和院内药品外流是长年趋势。 分析预计京东健康在 2 ...

Investment Rating - The report assigns a "Hold" rating for the company [6] Core Insights - The company is positioned as a leading player in the digital family office and AI investment community, focusing on integrating family office services with AI financial technology [7] - The family office business is expected to experience strong growth, with plans to increase the number of clients from 60 to 200 and assets under management (AUM) from $2.5 billion to over $10 billion by 2026 [7] - The report highlights the significant policy advantages in Hong Kong that support the family office sector, including tax incentives and regulatory flexibility [7] Financial Forecast - Revenue projections for the company are as follows: - 2024: HKD 202.40 million - 2025: HKD 189.70 million - 2026: HKD 257.40 million (growth of 35.69%) - 2027: HKD 332.60 million (growth of 29.22%) - 2028: HKD 438.85 million (growth of 31.95%) [2] - Net profit forecasts are: - 2024: HKD 99.90 million - 2025: HKD 136.80 million (growth of 36.94%) - 2026: HKD 362.17 million (growth of 164.74%) - 2027: HKD 421.81 million (growth of 16.47%) - 2028: HKD 474.51 million (growth of 12.49%) [2] - Earnings per share (EPS) estimates are: - 2024: HKD 0.07 - 2025: HKD 0.09 - 2026: HKD 0.17 - 2027: HKD 0.20 - 2028: HKD 0.23 [2] Company Overview - The company operates as a diversified financial group with a focus on family office services, traditional financial services, and digital finance [12] - It has a total share capital of 2.07 billion shares and a market capitalization of HKD 39.1 billion [3] - The company has experienced fluctuations in its stock price, with a 30-day average trading volume of 54.48 million shares [3] Business Segments - The main revenue sources for the company include: - Licensed financial services: 57.64% - Family office services: 28.12% [13] - The company has seen significant growth in its family office services, with revenue increasing nearly 3.3 times year-on-year [27]

Investment Rating - The report maintains a "Buy" rating for Yum China (09987.HK) [1] Core Insights - Yum China reported a 4% year-over-year increase in total revenue for the full year 2025, with a 9% increase in Q4 revenue, exceeding previous expectations [7] - The company achieved a net profit growth of 2% for the full year and 24% for Q4, attributed to automation, lean operations, and improved raw material costs [7] - The total number of stores reached 18,100 by the end of 2025, with a net addition of 1,706 stores throughout the year [7] - Same-store sales showed significant improvement, with a 1% increase for the full year and a 3% increase in Q4 [7] - The outlook for 2026 is positive, with plans to exceed 20,000 stores and a capital expenditure of $600-700 million [7] - The company plans to return $1.5 billion to shareholders in 2025, with a dividend yield of nearly 8% [7] - Earnings forecasts for 2026-2028 have been adjusted upwards, with projected net profits of $1.04 billion, $1.14 billion, and $1.26 billion respectively [7] Financial Summary - Total revenue projections for 2024 to 2028 are $11.30 billion, $11.80 billion, $12.69 billion, $13.43 billion, and $14.26 billion respectively, with year-over-year growth rates ranging from 2.96% to 7.54% [1] - Net profit projections for the same period are $911 million, $929 million, $1.04 billion, $1.14 billion, and $1.26 billion, with growth rates from 1.98% to 12.24% [1] - The latest diluted EPS estimates are $2.57, $2.62, $2.94, $3.23, and $3.56 for the years 2024 to 2028 [1] - The current P/E ratios are projected to decrease from 22.10 in 2024 to 15.94 in 2028 [1]

Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected stock price increase of over 15% within the next six months [4]. Core Insights - The company has signed a strategic research and development collaboration agreement with AstraZeneca, granting AstraZeneca exclusive global rights (excluding Greater China) to the company's weight management product portfolio, including a clinical-ready project SYH2082 and three preclinical projects. The company will receive an upfront payment of $1.2 billion, with potential milestone payments of up to $3.5 billion for research and $13.8 billion for sales, along with a double-digit percentage royalty on net sales [1][2]. - The collaboration marks an upgrade from single product licensing to platform licensing, reflecting AstraZeneca's strong recognition of the company's long-acting peptide and AI pharmaceutical technology platforms [1]. - The company is advancing its proprietary sustained-release drug delivery technology and AI drug discovery platform, which enhances patient compliance by allowing for monthly or longer dosing intervals [2]. Financial Summary - The company's projected revenues for 2025-2027 are estimated at 28.8 billion, 35.9 billion, and 32.5 billion CNY, respectively, with a compound annual growth rate (CAGR) of 24.62% in 2026 [3]. - The net profit attributable to the parent company is forecasted to be 5.34 billion, 7.87 billion, and 6.76 billion CNY for 2025-2027, with corresponding earnings per share (EPS) of 0.46, 0.68, and 0.59 CNY [3]. - The current market capitalization is approximately 112.23 billion HKD, with a total share count of 11,522 million [4].

盈利预测：（本表归母净利润为经调整后净利润口径） | [Table_Finance] | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 276,744 | 337,592 | 365,324 | 414,899 | 467,340 | | 增长率 （ % ） | 25.82% | 21.99% | 8.21% | 13.57% | 12.64% | | EBITDA（百万元） | 23,877 | 49,119 | -11,932 | 21,977 | 39,156 | | 归母净利润（百万元） | 23,253 | 43,772 | -22,518 | 7,219 | 23,982 | | EPS（元/股） | 3.72 | 7.15 | -3.73 | 1.21 | 4.04 | | 市盈率（x） | 22.41 | 11.68 | - | 68.71 | 20.68 | 数据来源：公司财务报表，广发证券发展研究中心（1 港币=0.8898 人民币） [Table_Pa ...